|
|
|
BEAM Dividend History & Description — Beam Therapeutics Inc
Beam Therapeutics is a biotechnology company. Co. has identified four development candidates to date: three from its ex vivo platform, with two candidates targeting hemoglobinopathies and one candidate targeting T-cell leukemia, and one from its in vivo platform targeting glycogen storage disease. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. When considering the Beam Therapeutics Inc stock dividend history, we have taken known splits into account, such that the BEAM dividend history is presented on a split-adjusted ("apples to apples") basis. Beam Therapeutics Inc dividend history is presented both in graphical/chart form, and as a BEAM dividend history data table along the right-hand column.
Name: |
Beam Therapeutics Inc |
Website: |
www.beamtx.com |
Sector: |
Biotechnology |
Number of ETFs Holding BEAM: |
37 (see which ones) |
Total Market Value Held by ETFs: |
$677,807,849.1 |
Total Market Capitalization: |
$2,713,000,000 |
% of Market Cap. Held by ETFs: |
24.98% |
|
BEAM Stock Dividend HistoryThe BEAM dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable BEAM historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the BEAM dividend history record. Also see the BEAM stock dividend history data table along the right-hand column below.
|
|
|
|
Buy (3.07 out of 4)
39th percentile
|
PARTNER NEWS:Tue, Feb 27, 2:39 PM, Zacks
Brian's Big Idea on Healthcare Big moving drug stocks and the HealthCare Innovators service at Zacks.
Thu, Feb 15, 4:45 AM, Zacks
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
|
|